Knowledge Hub
Knowledge Hub
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.
Written by NECNZ team
For people in Aotearoa living with a neuroendocrine tumour, somatostatin analogue injections are often part of long-term care – they can help slow tumour growth and ease hormone-driven symptoms. Until recently, long-acting octreotide was the only somatostatin analogue funded by Pharmac in this class. That changed in 2025.
Pharmac confirmed in February 2025 that it would fund lanreotide acetate, sold under the brand name Mytolac, from 1 March 2025 (60 mg and 120 mg strengths), with the 90 mg strength following from 1 April 2025. Funding covers neuroendocrine tumours, acromegaly, malignant bowel obstruction, and related indications including VIPomas, glucagonomas, gastrinomas, insulinomas and carcinoid syndrome. Eligibility for lanreotide aligns with the existing Special Authority criteria for long-acting octreotide, and people already on octreotide can switch to lanreotide without a new Special Authority approval.
Pharmac estimates that roughly 40 to 50 people will start on lanreotide each year. The medicine comes as a prefilled syringe, which can shorten preparation time for clinic staff and, in some cases, allow people to be trained to self-inject at home. Patients consulted by Pharmac highlighted the practical benefits: fewer clinic visits and the ability to travel for longer between doses. Mytolac will hold principal supply status from August/September 2025 through to 30 June 2027, meaning it will be the main funded brand during that window.
If you currently use octreotide, talk with your specialist or NET nurse about whether lanreotide might suit you. The two medicines are in the same class, and Pharmac has noted that no additional clinical benefit is expected – the difference is in how the medicine is given, how often you need to be at a clinic, and individual tolerability. NECNZ is happy to help you think through questions to bring to your next appointment.
Source 1: www.pharmac.govt.nz
Source 2: www.pharmac.govt.nz
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
In memory of Associate Professor Dr Malcolm Legget
Neuroendocrine Cancer New Zealand mourns the passing of Associate Professor Dr Malcolm Legget, a tireless advocate for NET patients.